STOK
NASDAQ · Biotechnology
Stoke Therapeutics Inc
$31.00
+0.74 (+2.45%)
Open$30.92
Previous Close$30.26
Day High$31.53
Day Low$29.84
52W High$40.22
52W Low$11.17
Volume—
Avg Volume703.7K
Market Cap1.93B
P/E Ratio—
EPS$-2.83
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+61.8% upside
Current
$31.00
$31.00
Target
$50.17
$50.17
$29.72
$50.17 avg
$68.67
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 201.63M | 323.22M | 315.22M |
| Net Income | -7,529,981 | -37,471,003 | -43,595,472 |
| Profit Margin | -3.7% | -11.6% | -13.8% |
| EBITDA | -20,576,338 | -52,091,948 | -53,358,586 |
| Free Cash Flow | — | -52,998,459 | -42,607,892 |
| Rev Growth | +145.9% | +14.4% | -1.8% |
| Debt/Equity | — | 0.58 | 0.65 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.93 | +0.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $352.99 | +1.72% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.88 | +0.66% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $478.81 | +2.22% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $626.31 | +1.34% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $300.33 | +4.22% | 64.3 | 37.13B |